BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, November 27, 2024
See today's BioWorld MedTech
Home
» Tricares raises $50M in series D for tricuspid heart valve replacement system
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Tricares raises $50M in series D for tricuspid heart valve replacement system
July 25, 2024
By
Shani Alexander
No Comments
Tricares SAS raised $50 million in a series D financing round to support upcoming clinical trials in the U.S. and EU for its transfemoral tricuspid heart valve replacement system, Topaz.
BioWorld MedTech
Financings
Series D
Europe
